New antibody analysis accelerates rational vaccine design
August 08, 2018 / The Scripps Research Institute
A team at Scripps Research has come up with a faster way to analyze the outcome of experimental vaccines against HIV and other pathogens. Their new system lets scientists quickly assess the full spectrum of antibodies produced in an individual in response to a pathogen or vaccine and determine if these antibodies are likely to be effective against the pathogen. "We can now watch antibody responses evolve almost in real time," says Lars Hangartner, Ph.D., a Scripps Research associate professor and co-senior author of the study, which published today in the journal Immunity.